An observational study in Breast Cancer-specific Survival, sponsored by Center of Personalized Medicine, Pirogova. Status unknown at 1 site in Russian Federation. Open to female participants aged Up to 70 Years. Per ClinicalTrials.gov, last updated 2021-03-16.
Sponsored by Center of Personalized Medicine, Pirogova · Observational
A population-based case-cohort study of breast cancer-specific survival among all first invasive breast cancer cases
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's planned enrollment of 3,000 is above the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Center of Personalized Medicine, Pirogova is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
All first invasive breast cancer cases from a National Cancer Registry
All women with stage I-III disease who survived at least 12 months post-diagnosis
Exclusion Criteria:
Unknown cause of death Treatment outside the region (thus precluding the treatment assessment)
Drug: neoadjuvant/adjuvant therapy
Drug: neoadjuvant/adjuvant therapy
chemotherapy/endocrine therapy/surgery/radiotherapy
The percentage of guideline-consistent and personalized EBM recommendations
The percentage of guideline-consistent and personalized EBM recommendations acted on by clinicians in patients with first invasive breast cancer. All discrepancies between routine and CDSS-recommended treatment resulting in frame of guideline-consistent therapy and personalized EBM therapy will be adjudicated by core laboratory.
Time frame: 3-year
Breast cancer-specific survival
All deaths due to breast cancer-related causes
Time frame: 3-year
Quantify the performance of the CDSS (MedicBK) algorithm
Quantify the performance of the CDSS (MedicBK) algorithm for presents treatment suggestions in frame of guideline-based therapy and personalized EBM therapy: the sensitivity, specificity, NPV, and PPV
Time frame: 3-year
Predictors
Predictors of guideline-consistent and personalized EBM adherence
Time frame: 3-year
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Center of Personalized Medicine, Pirogova